Literature DB >> 19073016

Comparative evaluation of flow-cytometric immunophenotyping and immunocytochemistry in the categorization of malignant small round cell tumors in fine-needle aspiration cytologic specimens.

Upasana Gautam1, Radhika Srinivasan, Arvind Rajwanshi, Deepak Bansal, Ram Kumar Marwaha.   

Abstract

BACKGROUND: The precise diagnosis of malignant small round cell tumors (MSRCTs) in fine-needle aspiration (FNA) cytology is a challenge that requires ancillary investigations. In this study, the authors evaluated the applicability of flow-cytometric immunophenotyping (FCI) and compared it with immunocytochemistry (ICC) for the accurate categorization of MSRCTs.
METHODS: In total, 37 consecutive MSRCTs that had been diagnosed with FNA cytology were analyzed by ICC and FCI using a panel of antibodies against desmin, vimentin, CD99/major histocompatibility class I-related antigen 2, neuron-specific enolase, and pancytokeratin. The final diagnoses included Ewing sarcoma (n = 17), rhabdomyosarcoma (n = 6; 4 embryonal and 2 alveolar subtypes), neuroblastoma (n = 10), desmoplastic small round cell tumor (n = 2), and retinoblastoma (n = 2).
RESULTS: Accurate categorization was possible in 67.5% of cases by ICC and in 64.8% of cases by FCI. Concordant immunophenotyping results with either technique were obtained in 21 cases (59.4%). Low cellularity of the sample and negativity for all markers tested were some limitations to both techniques when applied on fine-needle aspirates. However, using a combination of both techniques, 86.4% (32 of 37 cases) MSRCTs were typed accurately.
CONCLUSIONS: FCI is applicable on FNA material and complements ICC in accurate the typing of MSRCTs. This is particularly useful in advanced-stage disease, when neoadjuvant chemotherapy may be instituted promptly. (c) 2008 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19073016     DOI: 10.1002/cncr.23948

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  FNA diagnosis of CD99 positive neuroblastoma: A diagnostic dilemma.

Authors:  Gagandeep Kaur; Pooja Bakshi; Kusum Verma
Journal:  J Cytol       Date:  2012-04       Impact factor: 1.000

2.  Morphometric evaluation and clinical correlations in pediatric malignant small round cell tumors.

Authors:  Cherry Bansal; Archana Gupta; Archana Kumar; Anand Srivastava
Journal:  Indian J Med Paediatr Oncol       Date:  2014-10

Review 3.  Desmoplastic Small Round Blue Cell Tumor: A Review of Treatment and Potential Therapeutic Genomic Alterations.

Authors:  Ajaz Bulbul; Bridget Noel Fahy; Joanne Xiu; Sadaf Rashad; Asrar Mustafa; Hatim Husain; Andrea Hayes-Jordan
Journal:  Sarcoma       Date:  2017-11-01

4.  Benign Renal Tumors in Pediatric Age Group: Retrospective Analysis.

Authors:  Prema Menon; Katragadda Lakshmi Narasimha Rao; Saalim Nazki; Saswati Behera; Kirti Gupta; Ram Samujh; Shailesh Solanki; Akshay Saxena; Deepak Bansal; Amita Trehan
Journal:  J Indian Assoc Pediatr Surg       Date:  2021-11-12

5.  Effects of mPEG-DSPE/corannulene or perylene nanoparticles on the ovary and oocyte.

Authors:  Hongyu Wang; Jingwen Zhang; Daofu Feng; Xizeng Feng
Journal:  RSC Adv       Date:  2020-04-30       Impact factor: 3.361

6.  Contribution of multiparameter flow cytometry immunophenotyping to the diagnostic screening and classification of pediatric cancer.

Authors:  Cristiane S Ferreira-Facio; Cristiane Milito; Vitor Botafogo; Marcela Fontana; Leandro S Thiago; Elen Oliveira; Ariovaldo S da Rocha-Filho; Fernando Werneck; Danielle N Forny; Samuel Dekermacher; Ana Paula de Azambuja; Sima Esther Ferman; Paulo Antônio Silvestre de Faria; Marcelo G P Land; Alberto Orfao; Elaine S Costa
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

7.  Staging and monitoring of childhood rhabdomyosarcoma with flow cytometry.

Authors:  Hongqiang Shen; Yongmin Tang; Ao Dong; Huamei Li; Diying Shen; Shilong Yang; Hongfeng Tang; Weizhong Gu; Qiang Shu
Journal:  Oncol Lett       Date:  2014-02-04       Impact factor: 2.967

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.